Le Lézard
Classified in: Health
Subject: AWD

GT Medical Technologies, Inc.' GammaTile® Therapy Awarded


2023 Most Promising New Product of the Year by The Phoenix: The Medical Device and Diagnostic Conference for Chief Executive Officers

TEMPE, Ariz., Oct. 13, 2023 /PRNewswire/ -- GT Medical Technologies, Inc. a medical device company dedicated to improving the lives of patients with brain tumors, today announced that its FDA-cleared GammaTile® Therapy was awarded the 2023 Most Promising New Product of the Year by The Phoenix: The Medical Device and Diagnostic Conference for Chief Executive Officers. 

GammaTile® Therapy was awarded the 2023 Most Promising New Product of the Year

"We are honored to win this prestigious award from our industry peers," said GT Medical Technologies CEO Matthew Likens. "It's rewarding to be recognized by the Phoenix Conference as we all work together to help make the lives of our patients better."

GammaTile® Therapy is a Surgically Targeted Radiation Therapy (STaRT) for patients with newly diagnosed malignant intracranial neoplasms and patients with recurrent intracranial neoplasms. GammaTile® Therapy delivers immediate radiation that eradicates brain tumor cells before they can replicate post-surgery while helping to protect healthy brain tissue. GammaTiles are bioresorbable collagen embedded with radioactive seeds, Cesium 131. 

The award was announced at the 28th Annual Phoenix Conference on Thursday, October 12, 2023, in Half Moon Bay, Calif. GT Medical Technologies' GammaTile® Therapy joins past winners for Most Promising New Product of the Year, including the Intracept® System by Relievant, FlowTriever by Inari Medical, the Willow Pump by Willow and the Synthetic Cartilage Implant by Cartiva,

The Phoenix Awards are presented for outstanding achievements in the medical device and diagnostic industry to individuals and companies selected by industry CEOs. The conference is an invitation-only gathering of executives from large and small healthcare companies to discuss critical issues regarding the medical device industry. 

Since GammaTile® Therapy received FDA clearance in 2018 for recurrent brain tumors and in 2020 for newly diagnosed tumors, more than 1,000 patients have benefitted from its innovative design that targets any remaining cancer cells after a tumor is surgically removed.

About GT Medical Technologies, Inc.

Driven to raise the standard of care and improve the lives of patients with brain tumors, a team of brain tumor specialists formed GT Medical Technologies. FDA-cleared GammaTile Therapy is a Surgically Targeted Radiation Therapy (STaRT) for patients undergoing brain tumor removal surgery of newly diagnosed malignant and recurrent brain tumors. This treatment eliminates the need for one to six weeks of daily external beam radiation therapy, allowing patients to go about their daily lives without the burden of additional trips to the hospital or clinic for ongoing treatment. Since its full market release in the United States in March 2020, GammaTile has been offered in more than 95 hospitals, with more centers being added each month. For more information, visit www.gtmedtech.com and follow @GammaTile on Twitter and LinkedIn.

Media Contacts:

Lori Kagan
GT Medical Technologies
[email protected]

Dawn Fallon
New Dawn Communications
[email protected]

SOURCE GT Medical Technologies


These press releases may also interest you

at 04:45
ERS Genomics and IRBM Sign CRISPR/Cas9 License Agreement
ERS Genomics Limited (?ERS'), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS' CRISPR/Cas9 patent portfolio....

at 03:15
Cresilon Announces International Distribution Agreement for VETIGEL with Covetrus
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on haemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary haemostatic gel, VETIGEL®, to be sold directly...

at 02:30
New Research by Tea Advisory Panel Reveals That Three Quarters Of Brits Never Drink Tea Before A Workout Despite It Counting Towards Fluid Intake Recommendations
Ahead of International Tea Day - 21st May 2024  - and with summer inspiring more of us to get off the sofa to be active, a 2024 real-world research study1 reviewed by the tea science experts at the Tea Advisory Panel ? www.teaadvisorypanel.com -...

at 02:30
TREEFROG PRESENTS DATA FROM THEIR PARKINSON'S DISEASE CELL THERAPY PROGRAM AT THE 29TH WORLD CONGRESS ON PARKINSON'S DISEASE AND RELATED DISORDERS (IAPRD) IN LISBON
TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1]...

at 02:20
Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis
Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis...

at 02:07
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....

More news about Health...


News published on and distributed by: